omp-313m32
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 2, 2017 (NCT03119428)
Timeline
Indications
Mechanism of action
TIGIT antagonist
T-cell immunoreceptor with Ig and ITIM domains inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298205 ↗
Also known as
- omp-313m32
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05715216 | Phase 2 | Mar 24, 2023 | Mereo BioPharma, University of Texas at Houston |
| NCT05026606 | Phase 2 | Oct 1, 2021 | University of Texas at Houston |
| NCT04761198 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2021 | ICON, Mereo BioPharma |
| NCT03119428 | Phase 1 | May 2, 2017 | Mereo BioPharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 3 | 2 | 2 | 2017 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2021 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1